We've neglected Gilead Sciences for a while, but it's time for an update. Unfortunately, our entry looking back wasn't ideal, as the stock has fallen below the 61.8% retracement level. It found support just below the 78.6% level, which marks the bottom of our range. This level was precisely touched, and we saw a relatively good movement upward from...
Macrogenenics sold-off 75% from a moderately bad earnings miss 2 weeks ago. It will be a slow and gradual recovery in the 10 -12 weeks until the next earnings unless a favorable catalyst appears. 5 patients died in a clinical study about the same time as earnings were due. This was a news catalyst amplifying the earnings miss. What is unclear is the total...
JAN had earnings but I cannot find the report. It is trading with heavy volume and it shows in the price action. Price has pulled back in the after-market in a standard Fibonacci retracement. A pullback is appropriate here as price has gained 250% in a month. I see the pullback as healthy and JAN is now well positioned for another bullish continuation....
At some point there will be a boom biotechnology stocks. They haven't done much in the past ten years. I believe IBB will pass 250 within the decade. However, if the market remains stable, without any 20%+ corrections, I think IBB hits 250 to 300 in the next year
SRZN has had good momentum. It has no revenues. Clinical trials but a lot of cash. SRZN has advanced trials underway for a product to treat alcoholic hepatitis presumably settling it down before it becomes irreversible cirrhosis (only for patients who are alcohol-free) and also useful for liver metabolic disorders from a genetic basis. SRZN has been...
HRTX has been suggested by various trading websites as a potentially explosive penny biotech stock for 2024. It has experienced excellent price actions since an earnings beat in November. It beat the estimates; that is to say it burned about half as much cash as the analysts estimated the it would. Today it pumped 11%. Relevant articles can be found compiled...
This is a Technical Analysis on Moderna (MRNA) on the 1 Week Timeframe. Current price action shows that we are currently in the process of breaking a MAJOR SUPPORT Zone. We held critical SUPPORT multiple times ABOVE the $115.00 level, for a span of about 26 months. Expressed by the GREEN circles. But notice we havent been able to successfully rally and stay...
FULC on the 15 minute chart had a good response to favorable earnings and then retraced. It is now bounding off the Fib 0.5 level and also confluent with the POC line of the volume profile and the mean of the anchored VWAP. Buying volume appropriately overtook selling volume on the reversal Luxalgo's Echo indicator, an AI predictive tool, suggests a 10%...
Applied Therapeutics is an uptrending biotechnology company that has earnings in prior quarters and is heading into another earnings report about may 11th. The run up in price cction is largely on the proposition of future growth much like TSLA back in the day. On the chart besides the obvious uptrend, the volume indicator shows a dramatic volume surge...
- MA confluence on pullback - High RS - High ADR - Higher lows in base - Biotech
As shown on the daily chart dating back to last summer SIGA has been on a persistent decline since the cooling down from the parabolic breakout last summer. Is there a repeat in the picture? Fundamentally, earnings continue to be weak. much of the stock is held by insiders and the whole monkey pox thing is settled down although the main product may have use...
NVAX as seen on the weekly chart has been in price distress for a long time. It has only one product on the market due to various issues with the FDA process. It has a variety of products in development as linked below. The question is whether it will run out of cash before a sustained revenue stream develops. FDA approvals for the pipeline products could take...
3/16/23 - Enzo Biochem (ENZ) stock is rising higher on an asset sale agreement. It’s selling its Clinical Laboratory division to Labcorp (LH). 3/20/23 - Monthly GD on MC. 8/23/23 - $3 per share.
I've become interested in BZYR which trades only OTC at this time. Why is this OTC stock of high importance for long term investors? In order to set this out my post is broken into various parts: 1 - Introduction 2 - The historical battles 3 - Efficacy of a cancer treatment 4 - Summary 5 - The risk to reward for long term investors. The above cannot possibly...
Will it pull up the AdvisorShares Psychedelics ETF? Strength in the #Biotech sector would also be a friendly situation. here are the top holdings: CMPS COMPASS PATHWAYS PLC 13.12% ATAI ATAI LIFE SCIENCES NV 9.73% CYBN CYBIN INC 7.97% SEEL SEELOS THERAPEUTICS INC 6.90% ITCI INTRA-CELLULAR THERAPIES INC 6.44% HUGE FSD PHARMA INC-CLASS B 5.82% SAGE SAGE...
Biotechnology is the favorite sector of one of our analysts, most of his portfolio consists of biotechs, and he himself claims that it is the cryptocurrency of the common stock market. Why? Let's explain : High risk/reward and high volatility. Imagine this: you invest in a company that has no revenue or any specific product, yet you believe in the idea it...
Oversold likely due related to tax loss selling. Solid Q3 financials. Large insider buys. $10 price target from Scotiabank analyst.
SPDR S&P Biotech ETF ( AMEX:XBI ) Sector: Miscellaneous (Investment Trusts/Mutual Funds) Market Capitalization: $ -- Current Price: $81.20 Breakout price: $84.40 Buy Zone (Top/Bottom Range): $80.50-$74.75 Price Target: $99.10-$100.80 Estimated Duration to Target: 75-81d Contract of Interest: $XBI 12/16/22 85c Trade price as of publish date: $5.40/contract